Skip To Main Content
Amer M Zeidan on Muck Rack

Amer M Zeidan

New Haven
As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, PLOS, ScienceDirect, Taylor & Francis Online, Educational Studies, The New England Journal of Medicine, The Lancet and
Cancer doctor. Leukemia fighter. Hala @RealMadrid. Focus on #AMLsm & #MDSsm. Opinions are solely my own. COI bit.ly/2YfwJ9V
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amer M

Contact Amer M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Frontline AML: The All-Oral Evolution & Real-World Resilience

|
By Amer M Zeidan, Courtney DiNardo, Michael Savona
| ONCOLOGY journal Verified
Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care. Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML. Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.
Open in Who Shared Issue with article?

Are We Treating Diseases—or Genotypes? The Evolving Logic of AML Therapy

|
By Amer M Zeidan
| Blood Cancers Today Verified
Long gone are the days in which all fit patients with acute myeloid leukemia (AML) automatically get intensive chemotherapy (IC) with the 7+3 regimen.
Open in Who Shared Issue with article?

EHA 2026: Myeloid Disease Insights

|
By Amer M Zeidan
| Blood Cancers Today Verified
Photo Credit: iStock/matejmo I spend most of my clinical and research time in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), so that is where my attention went at this year’s European Hematology Association (EHA) congress.
Open in Who Shared Issue with article?
See all 86 licensed articles (205 Total)